Literature DB >> 20202482

Introduction to the reports from the National Cancer Institute First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.

Michael R Bishop, Edwin P Alyea, Mitchell S Cairo, J H Frederik Falkenburg, Carl H June, Nicolaus Kröger, Richard F Little, Jeffrey S Miller, Steven Z Pavletic, David Porter, Stanley R Riddell, Koen van Besien, Alan S Wayne, Daniel J Weisdorf, Roy Wu, Sergio Giralt.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20202482      PMCID： PMC2996879          DOI： 10.1016/j.bbmt.2010.02.025

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  16 in total

1.  Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time.

Authors:  A Gratwohl; R Brand; F Frassoni; V Rocha; D Niederwieser; P Reusser; H Einsele; C Cordonnier
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

2.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.

Authors:  H J Kolb; J Mittermüller; C Clemm; E Holler; G Ledderose; G Brehm; M Heim; W Wilmanns
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

3.  Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Authors:  E P Alyea; R J Soiffer; C Canning; D Neuberg; R Schlossman; C Pickett; H Collins; Y Wang; K C Anderson; J Ritz
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

4.  Approaches to leukemic relapse following bone marrow transplantation.

Authors:  R P Gale
Journal:  Transplant Proc       Date:  1978-03       Impact factor: 1.066

5.  Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases.

Authors:  F Frassoni; A J Barrett; A Grañena; P Ernst; G Garthon; H J Kolb; H G Prentice; J P Vernant; F E Zwaan; A Gratwohl
Journal:  Br J Haematol       Date:  1988-11       Impact factor: 6.998

6.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Authors:  R H Collins; O Shpilberg; W R Drobyski; D L Porter; S Giralt; R Champlin; S A Goodman; S N Wolff; W Hu; C Verfaillie; A List; W Dalton; N Ognoskie; A Chetrit; J H Antin; J Nemunaitis
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

7.  A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.

Authors:  David L Porter; Bruce L Levine; Nancy Bunin; Edward A Stadtmauer; Selina M Luger; Steven Goldstein; Alison Loren; Julie Phillips; Sunita Nasta; Alexander Perl; Steven Schuster; Donald Tsai; Ambika Sohal; Elizabeth Veloso; Stephen Emerson; Carl H June
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

8.  Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation.

Authors:  A Shimoni; J A Gajewski; M Donato; T Martin; S O'Brien; M Talpaz; A Cohen; M Korbling; R Champlin; S Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2001       Impact factor: 5.742

9.  Identical-twin (syngeneic) marrow transplantation for hematologic cancers.

Authors:  A Fefer; M A Cheever; P D Greenberg
Journal:  J Natl Cancer Inst       Date:  1986-06       Impact factor: 13.506

10.  Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia.

Authors:  Olle Ringdén; Myriam Labopin; Gerhard Ehninger; Dietger Niederwieser; Richard Olsson; Nadezda Basara; Juergen Finke; Rainer Schwerdtfeger; Matthias Eder; Donald Bunjes; Norbert-Claude Gorin; Mohamad Mohty; Vanderson Rocha
Journal:  J Clin Oncol       Date:  2009-08-03       Impact factor: 44.544
View more
  11 in total

Review 1.  Minimal residual disease following allogeneic hematopoietic stem cell transplantation.

Authors:  Nicolaus Kröger; Koichi Miyamura; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-01       Impact factor: 5.742

2.  Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation.

Authors:  Yoshihiro Inamoto; Mary E D Flowers; Stephanie J Lee; Paul A Carpenter; Edus H Warren; H Joachim Deeg; Rainer F Storb; Frederick R Appelbaum; Barry E Storer; Paul J Martin
Journal:  Blood       Date:  2011-06-01       Impact factor: 22.113

3.  Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.

Authors:  Nirali N Shah; Ulrike Bacher; Terry Fry; Katherine R Calvo; Maryalice Stetler-Stevenson; Diane C Arthur; Roger Kurlander; Kristin Baird; Barbara Wise; Sergio Giralt; Michael Bishop; Nancy M Hardy; Alan S Wayne
Journal:  Am J Hematol       Date:  2012-04-04       Impact factor: 10.047

4.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Developing Recommendations to Improve Survivorship and Long-Term Outcomes.

Authors:  Minoo Battiwalla; Shahrukh Hashmi; Navneet Majhail; Steven Pavletic; Bipin N Savani; Nonniekaye Shelburne
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-29       Impact factor: 5.742

5.  Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant.

Authors:  Catherine Matte-Martone; Srividhya Venkatesan; Hung Sheng Tan; Ioanna Athanasiadis; Julia Chang; Jovana Pavisic; Warren D Shlomchik
Journal:  J Immunol       Date:  2011-07-18       Impact factor: 5.422

6.  National Cancer Institute's First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee.

Authors:  Michael R Bishop; Edwin P Alyea; Mitchell S Cairo; J H Frederik Falkenburg; Carl H June; Nicolaus Kröger; Richard F Little; Jeffrey S Miller; Steven Z Pavletic; David L Porter; Stanley R Riddell; Koen van Besien; Alan S Wayne; Daniel J Weisdorf; Roy S Wu; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2011-01-09       Impact factor: 5.742

Review 7.  New frontiers in pediatric Allo-SCT: novel approaches for children and adolescents with ALL.

Authors:  M A Pulsipher; A S Wayne; K R Schultz
Journal:  Bone Marrow Transplant       Date:  2014-06-16       Impact factor: 5.483

8.  Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: introduction.

Authors:  Alan S Wayne; Sergio Giralt; Nicolaus Kröger; Michael R Bishop
Journal:  Biol Blood Marrow Transplant       Date:  2013-09-10       Impact factor: 5.742

9.  Factors predictive of relapse of acute leukemia in children after allogeneic hematopoietic cell transplantation.

Authors:  Nirali N Shah; Michael J Borowitz; Seth M Steinberg; Nancy C Robey; Christopher J Gamper; Heather J Symons; David M Loeb; Alan S Wayne; Allen R Chen
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-30       Impact factor: 5.742

10.  Immunotherapy for pediatric leukemia.

Authors:  Nirali N Shah; Hema Dave; Alan S Wayne
Journal:  Front Oncol       Date:  2013-07-01       Impact factor: 6.244
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.